Alliance to Develop Cell-Based Assays

Plans to collaborate on the development of cell-based assays have been announced by PerkinElmer, Inc. (Boston, MA, USA) and BioImage (Copenhagen, Denmark). The assays will be designed for the PerkinElmer EnVision HTS multilabel plate reader platform.

BioImage is a leader in using protein translocation-based technology to identify novel therapeutics. The collaboration combines the BioImage assay technology with PerkinElmer EnVision detection platform to develop a series of cell-based screening methods. BioImage has developed a suite of assay technologies for measuring protein-protein interactions in living cells using PerkinElmer's EnVision platform. The EnVision provides extremely sensitive fluorometric detection at high speeds, making it a good detection platform for the BioImage assays. This combination enables customers to perform robust cell-based identification of inhibitors of protein/protein interactions at throughput levels previously not available.

"This agreement provides a logical avenue for us to commercialize some of our technologies and collaborate with the leading provider of plate readers in the high- throughput screening market,” said Dr. Patrik Dahlen, CEO of BioImage. "We are actively out-licensing our IP [intellectual property] estate and marketing our assay development services, and are confident that the assays validated on the EnVision platform will be of great interest to many biopharmaceutical companies.”


Related Links:
PerkinElmer
BioImage